← All trials
NCT06439368
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jun 3, 2024
- Last posted
- Jun 3, 2024
- Enrollment
- 210
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yangtze River Pharmaceutical Group Co., Ltd.Lead sponsor
- Southern Medical UniversityCollaborator
- Southern Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.